Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G | Starlite/ChEMBL | No references |
Homo sapiens | isocitrate dehydrogenase 1 (NADP+), soluble | Starlite/ChEMBL | No references |
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 0.3514 | 0.3514 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 0.3514 | 0.3514 |
Toxoplasma gondii | isocitrate dehydrogenase | 0.0019 | 0 | 0.5 |
Plasmodium vivax | isocitrate dehydrogenase [NADP], mitochondrial, putative | 0.0019 | 0 | 0.5 |
Toxoplasma gondii | isocitrate dehydrogenase | 0.0019 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3514 | 1 |
Plasmodium falciparum | isocitrate dehydrogenase [NADP], mitochondrial | 0.0019 | 0 | 0.5 |
Trypanosoma brucei | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0019 | 0 | 0.5 |
Trypanosoma brucei | isocitrate dehydrogenase, putative | 0.0019 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3514 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3514 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3514 | 1 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 0.3514 | 0.3514 |
Onchocerca volvulus | 0.0182 | 1 | 0.5 | |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 0.3514 | 1 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 0.3514 | 1 |
Trypanosoma cruzi | isocitrate dehydrogenase, putative | 0.0019 | 0 | 0.5 |
Leishmania major | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0019 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable isocitrate dehydrogenase [NADP] Icd1 (oxalosuccinate decarboxylase) (IDH) (NADP+-specific ICDH) (IDP) | 0.0019 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.3514 | 1 |
Brugia malayi | RNA binding protein | 0.0076 | 0.3514 | 0.3514 |
Loa Loa (eye worm) | hypothetical protein | 0.0182 | 1 | 1 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 0.3514 | 0.3514 |
Trypanosoma cruzi | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0019 | 0 | 0.5 |
Brugia malayi | TAR-binding protein | 0.0076 | 0.3514 | 0.3514 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | > 89.214 uM | PUBCHEM_BIOASSAY: Luminescence-based cell-based high throughput dose response assay for biased ligands (agonists) of the melanocortin 4 receptor (MC4R). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 2.8184 uM | PubChem BioAssay. qHTS for Inhibitors of Vif-A3G Interactions: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 10.3225 uM | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 14.1254 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 17.7828 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 22.3872 uM | PubChem BioAssay. qHTS for Inhibitors of Glutaminase (GLS). (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.